Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Helen McShane
Woman and Man Max 99 years
Helen McShane
Update Il y a 4 ans
Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A
This trial will investigate the administration of two new tuberculosis vaccines, called AERAS-402 and MVA85A. The purpose of this trial is to assess what happens when both of these vaccine...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Professor Helen McShane
Update Il y a 4 ans
Aerosol BCG Challenge Trial in Healthy UK Adults
TB041 is a clinical challenge trial primarily to evaluate the safety of BCG challenge administered by the aerosol inhaled route in healthy, BCG naive UK adults. The trial will also look to...
Country
None
organs
None
Specialty
None
Opened trial
More information
Woman and Man Max 99 years
Helen McShane
Update Il y a 4 ans
A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV
This is an open Phase I study of a candidate TB vaccine, MVA85A, in healthy subjects who are infected with HIV. It is designed to study the safety and immunogenicity of the vaccine.
Country
Senegal
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Helen McShane
Update Il y a 4 ans
A Study to Quantify Bacille Calmette Guerin (BCG) and Characterise the Immune Response After BCG Vaccination
This is a human pilot study of 16 healthy BCG-naïve volunteers to quantify BCG from the BCG vaccination site. Volunteers will be vaccinated with BCG. The first 8 will go on to have a punch...
Country
United Kingdom
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Helen McShane, MD and PhD
Update Il y a 4 ans
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG
This is a phase I study to examine the safety and immunogenicity of MVA85A delivered intradermally into the deltoid region in volunteers who have recieved BCG in the past 20 years.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Helen McShane
Update Il y a 4 ans
A Phase I Study to Assess the Safety and Immunogenicity of Tuberculosis (TB) Vaccine Candidates FP85A and MVA85A
This is a Phase I study whose primary outcome is to assess the safety of a new tuberculosis vaccine, FP85A, when administered individually and sequentially with MVA85A in a prime-boost reg...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Helen McShane
Update Il y a 4 ans
A Study of 2 Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Previously Vaccinated With BCG
The dose of recombinant MVA used in the TB trials to date is relatively low compared with other trials using recombinant MVAs which have used up to 2.5 x 108pfu (A Hill, personal communica...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Helen McShane
Update Il y a 4 ans
A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both
This study is designed to evaluate the safety of MVA85A in asymptomatic volunteers in South Africa who are infected with M.tb, HIV or both. A single vaccination with MVA85A, when administe...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Helen McShane
Update Il y a 4 ans
Safety and Immunogenicity of MVA85A in Volunteers Latently Infected With TB
This study is designed to evaluate the safety of MVA85A in healthy volunteers in the UK who are latently infected with M.tb. A single vaccination with MVA85A, when administeredat a dose of...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Helen McShane, MD and PhD
Update Il y a 4 ans
A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers
This study is to assesss the safety and immunogenicity of vaccine based on Modified Vaccinia Ankara (MVA) expressing the 85A antigen (from Mycobacterium. tuberculosis). This vaccine is del...
Country
None
organs
None
Specialty
None
Closed trial
More information
1
2
3
Next